A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.
